Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group

被引:19
|
作者
Favalli, G
Vermorken, JB
Vantongelen, K
Renard, J
Van Oosterom, AT
Pecorelli, S
机构
[1] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium
[2] Univ Brescia, Spedali Civili, Dept Gynecol Oncol, Brescia, Italy
[3] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium
[4] Eortc Data Ctr, Brussels, Belgium
关键词
quality control; multicentric trials; chemotherapy;
D O I
10.1016/S0959-8049(00)00090-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Data Quality is a central requirement of scientific research and external monitoring is essential in multicentric clinical trials (MCT). A quality control (QC) study was conducted in the main Institutions participating in EORTC-GCCG Protocol number 55863 - randomised phase III trial of vindesine. cisplatin, bleomycin and mitomycin-C (BEMP) versus cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix - in order to assess the impact of variations in data quality on the conclusions of the trial. The reliability of the different centres in following the protocol was investigated by a questionnaire covering drug prescription, local facilities and the procedure for preparation and administration of chemotherapy. The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy. 'Data quality control' was assessed by comparison of data on case report forms (CRFs) with the corresponding items in the medical records. Eleven centres participating in the trial were visited by the same team of reviewers. Striking differences were noted in the chemotherapy administration procedures and between the type and quality of hospital files. Overall. there was an acceptable level of data quality and protocol compliance. Data accuracy was 81.8% (range: 65.6-97%) of the 4424 items checked. Incorrect data were found in 7.0% (2.3-14.5%), data were missing on the form in 3.6% of cases (0-12%) and data was on the form but not in the file in 7.6% of cases (0.7-17.5%). Causes of inaccuracy were analysed. Both problems in data management but also in a lack of clarity of the protocol and/or CRFs were to blame. Training and supervision of data managers, precision in writing protocols, standardisation of some aspects of CRFs and the use of a checklist for chemotherapy data and treatment toxicities would have avoided many of these errors. The need for QC in all collaborative groups performing MCT is emphasised. A literature review on QC in MCT dealing with chemotherapy is included. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1125 / 1133
页数:9
相关论文
共 50 条
  • [41] Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
    Hayoz, Stefanie
    Kasenda, Benjamin
    Schenker, Annina Lea
    Kopp, Christoph
    Schar, Sami
    Thurlimann, Beat
    von Moos, Roger
    Pless, Miklos
    BMJ OPEN, 2023, 13 (04):
  • [42] Pharmaceutical involvement in breast cancer clinical trials.
    Peppercorn, JM
    Blood, E
    Winer, EP
    Partridge, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 542S - 542S
  • [43] Premature termination of genitourinary cancer clinical trials.
    Stensland, Kristian D.
    McBride, Russell
    Wisnivesky, Juan P.
    Latif, Asma
    Hendricks, Ryan
    Roper, Nitin
    Boffetta, Paolo
    Hall, Simon J.
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [44] Fulfillment of the uncertainty principle in cancer clinical trials.
    Joffe, S
    Harrington, DP
    George, SL
    Emanuel, EJ
    Budzinski, L
    Weeks, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 519S - 519S
  • [45] Attitudes of patients towards cancer clinical trials.
    Ayodele, Olubukola
    Akhtar, Mateen
    Eastwood, Mathew Chad
    Linkeviciute-Koneko, Aiste
    Keegan, Niamh M.
    Calacsan, Flordeliza
    O'Connor, Miriam
    Calvert, Paula
    Horgan, Anne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] Molecular imaging as a cancer biomarker in clinical trials.
    Mankoff, D.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 25 - 26
  • [47] Quality of Life as an Outcome Measure for Epilepsy Clinical Trials.
    Joyce A. Cramer
    Pharmacy World and Science, 1997, 19 : 227 - 230
  • [48] A review of health-related quality of life assessment in EORTC cancer clinical trials
    Zikos, Efstathios
    Coens, Corneel
    Sprangers, Mirjam A. G.
    Ediebah, Divine Ewane
    Greimel, Eva Elfriede
    Flechtner, Henning H.
    Bottomley, Andrew
    QUALITY OF LIFE RESEARCH, 2013, 22
  • [49] Voluntary submission of biological specimens from cancer clinical trials: An update of the Eastern Cooperative Oncology Group experience
    Jenab-Wolcott, J.
    Catalano, P. J.
    Fillingham, B.
    Ferriere, M.
    O'Dwyer, P. J.
    Giantonio, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] QUALITY OF LIFE OUTCOMES IN EORTC CANCER CLINICAL TRIALS: WHAT'S BEEN THE IMPACT?
    Flechtner, Henning
    Bottomley, Andrew
    Efficace, Fabio
    Vanvoorden, Veerle
    Coens, Corneel
    Therasse, Patrick
    Velikova, Galina
    Blazeby, Jane
    Greimel, Eva
    QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2052 - 2052